Background: Adenomyosis is caused by endometrial glands and stroma invading the myometrium. It is more common in parturients after the age of 30. At present, there are many drugs for the treatment of adenomyosis, and drug treatment is also one of the important treatments for adenomyosis. Objective: To summarize the drugs that can be used for the treatment of adenomyosis, hoping to be helpful to the clinical treatment. Method: Relevant studies were retrieved from the MEDLINE, Embase, Cochrane Library, CENTRAL and ClinicalTrials.gov. The retrieval time range was from January 2000 to March 2022. English search terms included "(treatment)","(adenomyosis) OR (endometrioma) OR (adenomyoma)". Result: Drug therapy can relieve the clinical symptoms of patients, inhibit the proliferation of lesions, and cooperate with surgical treatment to improve the curative effect. The efficacy and adverse reactions of the drug are closely related to the duration of use. At present, there is no specific drug for the treatment of adenomyosis, and there is a certain degree of recurrence after drug withdrawal. Some clinical scholars have adopted a combination regimen for the treatment of adenomyosis and achieved certain results. Conclusion: About the drug treatment of adenomyosis, it is necessary to personalize the treatment plan by combining the severity of the patients' clinical symptoms, age, fertility needs, patients' economic conditions, whether they can regulate the use of drugs, and the adverse reactions after the use of drugs.
| Published in | Journal of Gynecology and Obstetrics (Volume 10, Issue 2) |
| DOI | 10.11648/j.jgo.20221002.22 |
| Page(s) | 139-143 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Adenomyosis, Drug Treatment, Review
| [1] | Chapron Charles, Vannuccini Silvia, Santulli Pietro et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. [J]. Hum Reprod Update, 2020, 26: 392-411. |
| [2] | Donnez Jaques, Squifflet Jean, Pirard Céline et al. The efficacy of medical and surgical treatment of endometriosis-associated infertility and pelvic pain. [J]. Gynecol Obstet Invest, 2002, null: 2-7; discussion 7-10. |
| [3] | Rathinam Kiran Kumar, Abraham Justin Jacob, S Heema Preethy et al. Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review. [J]. Eur J Clin Pharmacol, 2022, undefined: undefined. |
| [4] | Haiyan Sun, Lin Wang, Shuhua Huang et al. High-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone analogs (GnRHa) and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis: a case series with long-term follow up. [J]. Int J Hyperthermia, 2019, 36: 1179-1185. |
| [5] | Song Soo Youn, Lee Sun Yeul, Kim Hye Yun et al. Long-term efficacy and feasibility of levonorgestrel-releasing intrauterine device use in patients with adenomyosis. [J]. Medicine (Baltimore), 2020, 99: e20421. |
| [6] | Kriplani A., Singh B M, Lal S et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. [J]. Int J Gynaecol Obstet, 2007, 97: 190-194. |
| [7] | Hirata Tetsuya, Izumi Gentaro, Takamura Masashi et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. [J]. Gynecol Endocrinol, 2014, 30: 726-729. |
| [8] | Foster R H, Wilde M I. Dienogest. [J]. Drugs, 1998, 56: 825-833; discussion 834-835. |
| [9] | Donnez Jacques, Dolmans Marie-Madeleine. Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review. [J]. J Clin Med, 2021, 10: 1085. |
| [10] | Osuga Yutaka, Fujimoto-Okabe Haruka, Hagino Atsushi. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. [J]. Fertil Steril, 2017, 108: 673-678. |
| [11] | Mehdizadeh Kashi Abolfazl, Niakan Gelareh, Ebrahimpour Majid et al. A randomized, double-blind, placebo-controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis. [J]. Int J Gynaecol Obstet, 2022, 156: 124-132. |
| [12] | Bedaiwy Mohamed A, Allaire Catherine, Alfaraj Sukinah. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. [J]. Fertil Steril, 2017, 107: 537-548. |
| [13] | Carvalho Nelsilene, Margatho Deborah, Cursino Kleber et al. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. [J]. Fertil Steril, 2018, 110: 1129-1136. |
| [14] | Margatho Deborah, Carvalho Nelsilene Mota, Bahamondes Luis. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. [J]. Eur J Contracept Reprod Health Care, 2020, 25: 133-140. |
| [15] | Li Jin-Jiao, Chung Jacqueline P W, Wang Sha et al. The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility. [J]. Biomed Res Int, 2018, 2018: 6832685. |
| [16] | Alcalde Ana María, Martínez-Zamora María Ángeles, Gracia Meritxell et al. Assessment of Quality of Life, Sexual Quality of Life, and Pain Symptoms in Deep Infiltrating Endometriosis Patients With or Without Associated Adenomyosis and the Influence of a Flexible Extended Combined Oral Contraceptive Regimen: Results of a Prospective, Observational Study. [J]. J Sex Med, 2022, 19: 311-318. |
| [17] | Benetti-Pinto Cristina Laguna, Mira Ticiana Aparecida Alves de, Yela Daniela Angerame et al. Pharmacological Treatment for Symptomatic Adenomyosis: A Systematic Review. [J]. Rev Bras Ginecol Obstet, 2019, 41: 564-574. |
| [18] | Hassanin Ahmed I, Youssef Ahmed A, Yousef Asmaa M et al. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial. [J]. Int J Gynaecol Obstet, 2021, 154: 263-269. |
| [19] | Wu Debin, Hu Min, Hong Li et al. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. [J]. Arch Gynecol Obstet, 2014, 290: 513-523. |
| [20] | Sauerbrun-Cutler May-Tal, Alvero Ruben. Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture. [J]. Fertil Steril, 2019, 112: 799-803. |
| [21] | Li Qiuju, Yuan Ming, Li Ni et al. The efficacy of medical treatment for adenomyosis after adenomyomectomy. [J]. J Obstet Gynaecol Res, 2020, 46: 2092-2099. |
| [22] | Pang Li-Li, Mei Jin, Fan Ling-Xiu et al. Efficacy of High-Intensity Focused Ultrasound Combined With GnRH-a for Adenomyosis: A Systematic Review and Meta-Analysis. [J]. Front Public Health, 2021, 9: 688264. |
| [23] | Peng Yan, Dai Yu, Yu Guiyuan et al. Clinical evaluation of HIFU combined with GnRH-a and LNG-IUS for adenomyosis patients who failed to respond to drug therapies: two-year follow-up results. [J]. Int J Hyperthermia, 2021, 38: 1271-1275. |
| [24] | Qin Xiaoyan, Sun Wenjing, Wang Chong et al. Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis. [J]. Reprod Biol Endocrinol, 2021, 19: 114. |
| [25] | Che Xuan, Wang Jianzhang, He Jiayi et al. A new trick for an old dog: The application of mifepristone in the treatment of adenomyosis. [J]. J Cell Mol Med, 2020, 24: 1724-1737. |
| [26] | Fattori Victor, Franklin Noah S, Gonzalez-Cano Rafael et al. Nonsurgical mouse model of endometriosis-associated pain that responds to clinically active drugs. [J]. Pain, 2020, 161: 1321-1331. |
| [27] | Jerusalem G, Farah S, Courtois A et al. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. [J]. Ann Oncol, 2021, 32: 1256-1266. |
| [28] | Badawy Ahmed M, Elnashar Aboubakr M, Mosbah Alaa A, Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. [J]. Acta Obstet Gynecol Scand, 2012, 91: 489-495. |
APA Style
Zhenyue Qin, Zhiyong Dong, Junling Liu, Shoufeng Zhang, Huihui Wang, et al. (2022). Research Progress in Drug Treatment of Adenomyosis. Journal of Gynecology and Obstetrics, 10(2), 139-143. https://doi.org/10.11648/j.jgo.20221002.22
ACS Style
Zhenyue Qin; Zhiyong Dong; Junling Liu; Shoufeng Zhang; Huihui Wang, et al. Research Progress in Drug Treatment of Adenomyosis. J. Gynecol. Obstet. 2022, 10(2), 139-143. doi: 10.11648/j.jgo.20221002.22
AMA Style
Zhenyue Qin, Zhiyong Dong, Junling Liu, Shoufeng Zhang, Huihui Wang, et al. Research Progress in Drug Treatment of Adenomyosis. J Gynecol Obstet. 2022;10(2):139-143. doi: 10.11648/j.jgo.20221002.22
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.jgo.20221002.22,
author = {Zhenyue Qin and Zhiyong Dong and Junling Liu and Shoufeng Zhang and Huihui Wang and Mingyue Bao and Weiwei Wei and Ruxia Shi and Jiming Chen and Bairong Xia},
title = {Research Progress in Drug Treatment of Adenomyosis},
journal = {Journal of Gynecology and Obstetrics},
volume = {10},
number = {2},
pages = {139-143},
doi = {10.11648/j.jgo.20221002.22},
url = {https://doi.org/10.11648/j.jgo.20221002.22},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20221002.22},
abstract = {Background: Adenomyosis is caused by endometrial glands and stroma invading the myometrium. It is more common in parturients after the age of 30. At present, there are many drugs for the treatment of adenomyosis, and drug treatment is also one of the important treatments for adenomyosis. Objective: To summarize the drugs that can be used for the treatment of adenomyosis, hoping to be helpful to the clinical treatment. Method: Relevant studies were retrieved from the MEDLINE, Embase, Cochrane Library, CENTRAL and ClinicalTrials.gov. The retrieval time range was from January 2000 to March 2022. English search terms included "(treatment)","(adenomyosis) OR (endometrioma) OR (adenomyoma)". Result: Drug therapy can relieve the clinical symptoms of patients, inhibit the proliferation of lesions, and cooperate with surgical treatment to improve the curative effect. The efficacy and adverse reactions of the drug are closely related to the duration of use. At present, there is no specific drug for the treatment of adenomyosis, and there is a certain degree of recurrence after drug withdrawal. Some clinical scholars have adopted a combination regimen for the treatment of adenomyosis and achieved certain results. Conclusion: About the drug treatment of adenomyosis, it is necessary to personalize the treatment plan by combining the severity of the patients' clinical symptoms, age, fertility needs, patients' economic conditions, whether they can regulate the use of drugs, and the adverse reactions after the use of drugs.},
year = {2022}
}
TY - JOUR T1 - Research Progress in Drug Treatment of Adenomyosis AU - Zhenyue Qin AU - Zhiyong Dong AU - Junling Liu AU - Shoufeng Zhang AU - Huihui Wang AU - Mingyue Bao AU - Weiwei Wei AU - Ruxia Shi AU - Jiming Chen AU - Bairong Xia Y1 - 2022/04/20 PY - 2022 N1 - https://doi.org/10.11648/j.jgo.20221002.22 DO - 10.11648/j.jgo.20221002.22 T2 - Journal of Gynecology and Obstetrics JF - Journal of Gynecology and Obstetrics JO - Journal of Gynecology and Obstetrics SP - 139 EP - 143 PB - Science Publishing Group SN - 2376-7820 UR - https://doi.org/10.11648/j.jgo.20221002.22 AB - Background: Adenomyosis is caused by endometrial glands and stroma invading the myometrium. It is more common in parturients after the age of 30. At present, there are many drugs for the treatment of adenomyosis, and drug treatment is also one of the important treatments for adenomyosis. Objective: To summarize the drugs that can be used for the treatment of adenomyosis, hoping to be helpful to the clinical treatment. Method: Relevant studies were retrieved from the MEDLINE, Embase, Cochrane Library, CENTRAL and ClinicalTrials.gov. The retrieval time range was from January 2000 to March 2022. English search terms included "(treatment)","(adenomyosis) OR (endometrioma) OR (adenomyoma)". Result: Drug therapy can relieve the clinical symptoms of patients, inhibit the proliferation of lesions, and cooperate with surgical treatment to improve the curative effect. The efficacy and adverse reactions of the drug are closely related to the duration of use. At present, there is no specific drug for the treatment of adenomyosis, and there is a certain degree of recurrence after drug withdrawal. Some clinical scholars have adopted a combination regimen for the treatment of adenomyosis and achieved certain results. Conclusion: About the drug treatment of adenomyosis, it is necessary to personalize the treatment plan by combining the severity of the patients' clinical symptoms, age, fertility needs, patients' economic conditions, whether they can regulate the use of drugs, and the adverse reactions after the use of drugs. VL - 10 IS - 2 ER -
Information
Email: